secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2024-08-27T23:59:59+00:00
Accession:  0001193125-24-207814
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Verrica CCO Joe Bonaccorso resigns effective Aug 30, 2024; consulting role through Aug 2025
--------------------------------------------------------------------------------

- Joe Bonaccorso resigns as Chief Commercial Officer effective August 30, 2024.
- Separation benefits include 12 months base salary and up to 12 months COBRA coverage.
- Consulting Agreement runs through August 30, 2025, with no cash compensation; outstanding equity continues vesting.
- Company expects to enter into Release and Consulting Agreements with Bonaccorso.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524207814/0001193125-24-207814-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524207814/d890208d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-207814

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer